Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
nexium · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Nexium + Yoghurt | ACTIVE_COMPARATOR | - |
| Nexium + Placebo | PLACEBO_COMPARATOR | - |
| Placebo+ Yoghurt | PLACEBO_COMPARATOR | - |
| placebo+placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| nexium | DRUG | 40 mg once daily is tested together with Yoghurt |
| Yoghurt | DIETARY_SUPPLEMENT | Yoghurt |
| placebo+placebo | DRUG | placebo and placebo are tested. |
Inclusion Criteria: * Type 2 diabetes (WHO criteria) treated with metformin and/or sulfonylureas or diet * Males and females between 40 and 70 years * HbA1c between 6,0-10,0 * Diabetes duration \> 1 year Exclusion Criteria: * Kidney disease (s-creatinine above the upper limit of normal range). * ...
Top 20 of 31 competitors
Nexium is being studied for its effect on insulin secretion and cardiovascular risk factors in patients with Type 2 Diabetes. It is an investigational small molecule in Phase 3 clinical development for this indication. The drug is being evaluated in a randomized, double-blind, placebo-controlled trial.
Nexium is being developed by Novo Nordisk A/S, a biopharmaceutical company listed on the stock exchange under the ticker NVO. The company is conducting clinical research to evaluate the drug's potential in treating Type 2 Diabetes.
Nexium is in Phase 3 clinical development for Type 2 Diabetes. It is an investigational drug, meaning it has not been approved for this use and is still undergoing clinical trials to assess its safety and efficacy.
Nexium is being studied in a Phase 3 clinical trial with the identifier NCT00699426. The trial is titled "The Effect of Nexium and Probiotics on Insulin Secretion and Cardiovascular Risk Factors in Patients With Type 2 Diabetes" and has been completed. The study enrolled 41 participants aged 40 years and older.
Nexium is the brand name for esomeprazole, a proton pump inhibitor. In the context of this clinical trial, Nexium is being investigated for its potential effects on insulin secretion and cardiovascular risk factors in patients with Type 2 Diabetes.